What 9 Analyst Ratings Have To Say About Karuna Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past three months, nine analysts have published their opinions on Karuna Therapeutics (NASDAQ:KRTX) stock. The average price target is $261.22, representing a 5.61% decrease from the previous average price target of $276.75. The majority of the ratings are bullish.
September 28, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Karuna Therapeutics has received mostly bullish ratings from analysts, but the average price target has decreased by 5.61%.
The majority of the analysts have given bullish ratings to Karuna Therapeutics, indicating a positive outlook for the stock. However, the decrease in the average price target suggests that the analysts have lowered their expectations for the stock's performance, which could potentially impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100